Adam Brufsky

TL;DR: A 67-year-old woman with breast cancer who presented with a history of progressive oropharyngeal dysphagia as a paraneoplastic neurologic complication was diagnosed with invasive ductal carcinoma, nuclear grade 3 with moderate peritumoral lymphoid infiltrate as discussed by the authors.

TL;DR: A Susan G. Komen -funded clinical trial of chemo-immunotherapy using the immunomodulatory drug gemcitabine with a dendritic cell vaccine pulsed with six HLA-A2-presented TBVA-derived peptides is proposed to determine vaccine-induced generation ofTBVA-Tc1 immunity and clinical response.

TL;DR: In this article , the authors measured dose reductions, early terminations, and overall dose intensity of ESBC chemotherapy in urban breast cancer centers and compared by race, using a longitudinal, comparative descriptive design, treatment characteristics were measured in women receiving ESBC cancer chemotherapy in seven cancer centers in Western PA and Eastern Ohio.

TL;DR: The experience at the University of Pittsburgh Medical Center has demonstrated that a clinical pathways program can reduce unwarranted variability in both treatment and outcomes, drive adherence to evidence-based medicine, and, in the process, reduce the growth rate in the total costs of cancer care.